No official summary available for this bill.
[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 5699 Introduced in House (IH)]
<DOC>
118th CONGRESS
1st Session
H. R. 5699
To provide programs to assist diagnosis, awareness, and education of
blood clot conditions, and for other purposes.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
September 26, 2023
Ms. Blunt Rochester (for herself, Mr. Bucshon, Mr. Burgess, and Mr.
Tonko) introduced the following bill; which was referred to the
Committee on Energy and Commerce
_______________________________________________________________________
A BILL
To provide programs to assist diagnosis, awareness, and education of
blood clot conditions, and for other purposes.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Charles Rochester Blood Clot
Prevention and Treatment Act''.
SEC. 2. FINDINGS.
Congress finds the following:
(1) Deep venous thrombosis (in this Act referred to as
``DVT'') occurs when blood clots form in the legs, pelvis, or
arms, and the most serious complications occur when a part of
the clot breaks off and travels to the lungs, causing a
blockage called pulmonary embolism (in this Act referred to as
``PE'').
(2) According to the Centers for Disease Control and
Prevention, 1 American dies every 6 minutes as a result of a
blood clot, and 1 in 4 people who have a PE die without
warning.
(3) The Centers for Disease Control and Prevention has
estimated that about 900,000 people suffer from DVT/PE per year
and 100,000 people die each year from blood clots, but also
recognizes that the precise number of people affected by DVT/PE
is unknown.
(4) These numbers are estimated because currently there is
no systematic collection of DVT/PE-related morbidity or
mortality data in the United States.
(5) Blood clots can affect anyone, but certain risk factors
make certain individuals more susceptible, including pregnancy,
cancer, hospitalizations, obesity, older age, and African
American race.
(6) The overall incidence of DVT and PE is 30 to 60 percent
higher in Black Americans, who also have a higher rate of 30-
day mortality compared with White Americans.
(7) The direct and indirect cost of blood clots is more
than $10,000,000,000 annually.
(8) Early diagnosis of a DVT is one of the most important
factors in preventing a PE.
SEC. 3. PUBLIC EDUCATION, AWARENESS, AND DIAGNOSIS OF DVT/PE.
Part J of title III of the Public Health Service Act (42 U.S.C.
280b et seq.) is amended by inserting after section 393D the following:
``SEC. 393E. PREVENTION OF MORBIDITY AND MORTALITY AS A RESULT OF DEEP
VENOUS THROMBOEMBOLISM.
``(a) In General.--The Secretary, acting through the Director of
the Centers for Disease Control and Prevention, (in this section
referred to as the `Secretary') shall carry out projects to increase
education, awareness, or diagnosis of deep venous thrombosis (in this
section referred to as `DVT') or pulmonary embolism (in this section
referred to as `PE') and to reduce the incidence of morbidity and
mortality caused by blood clots. Such projects may be carried out by
the Secretary directly or through awards of grants or contracts to
public or nonprofit private entities. The Secretary may directly (or
through such awards) provide technical assistance with respect to the
planning, development, and operation of such projects.
``(b) Projects.--A project under this section may include--
``(1) the implementation of public information and
education programs for--
``(A) the prevention of death from DVT/PE;
``(B) broadening the awareness of the public
concerning--
``(i) the risk factors for and the symptoms
of DVT/PE;
``(ii) target populations with greater risk
for DVT/PE, including women, seniors, cancer
patients, hospitalized patients, pregnant and
postpartum women, Black Americans, and those in
rural areas; and
``(iii) the public health consequences of
DVT/PE; and
``(C) increasing screening, detection, and
diagnosis of DVT/PE; and
``(2) surveillance of the prevalence and incidence of DVT/
PE to improve patient outcomes.
``(c) Grant and Contract Prioritization.--The Secretary may, in
awarding grants or entering into contracts under this section, give
priority to entities seeking to carry out projects that target the
populations referred to in subsection (b)(1)(B)(ii).
``(d) Coordination of Activities.--The Secretary shall ensure that
projects carried out under this section are coordinated, as
appropriate, with other agencies of the Public Health Service that
carry out activities regarding DVT/PE.
``(e) Best Practices.--The Secretary shall--
``(1) collect and analyze the findings of research
conducted with respect to DVT/PE; and
``(2) taking into account such findings, publish on the
website of the Centers for Disease Control and Prevention best
practices for physicians and other health care providers who
provide care to individuals with DVT/PE.''.
SEC. 4. ADVISORY COMMITTEE FOR DVT/PE PREVENTION.
(a) Establishment.--Not later than 180 days after the date of
enactment of this Act, the Secretary of Health and Human Services (in
this section referred to as the ``Secretary'') shall establish an
advisory committee to be known as the ``Advisory Committee for DVT/PE
Prevention'' (in this section referred to as the ``Advisory
Committee'').
(b) Duties.--The Advisory Committee shall--
(1) identify the aggregate number of individuals in the
United States who experience DVT/PE annually;
(2) identify how data are collected regarding DVT/PE and
the adverse outcomes associated with such conditions;
(3) identify how DVT/PE impacts the lives of individuals in
the United States;
(4) identify the standard of care for DVT/PE surveillance,
detection, and treatment;
(5) identify emerging treatments, therapies, and research
relating to DVT/PE;
(6) develop recommendations to help health care providers
identify patients who may be at a higher risk of forming DVT/PE
in health care facilities;
(7) develop recommendations to help improve patient
awareness of DVT/PE;
(8) develop recommendations with respect to the standard of
care for patients at risk of forming DVT/PE;
(9) develop recommendations relating to providing patients
and their families with written notice of increased risks of
forming DVT/PE; and
(10) identify the estimated level of Federal funding needed
for DVT/PE services to meet the needs of high-risk populations.
(c) Membership.--The Advisory Committee shall be composed of
members appointed by the Secretary as follows:
(1) At least 1 individual who has experienced blood clots.
(2) At least 1 family member of an individual who died from
DVT/PE.
(3) At least 1 health services researcher.
(4) At least 1 health care provider.
(5) At least 1 representative of a health plan.
(6) At least 1 representative of a hospital or health
system.
(7) At least 1 epidemiologist.
(8) At least 1 public health expert.
(9) At least 1 patient representative or representative of
a patient group.
(10) Such individuals representing other interested parties
or associations, as the Secretary determines appropriate.
(d) Report.--Not later than 18 months after the first meeting of
the Advisory Committee, the Secretary shall submit to Congress (and
make publicly available) a report--
(1) summarizing the meetings and findings of the Advisory
Committee; and
(2) describing the recommendations of the Advisory
Committee for legislative or administrative action to improve
DVT/PE prevention, treatment, and diagnosis, including the
recommendations described in paragraphs (6) through (9) of
subsection (b).
(e) Termination.--The Advisory Committee shall terminate on the
earlier of--
(1) the date on which the Secretary submits the report
under subsection (d); and
(2) the date that is 18 months after the first meeting of
the Advisory Committee.
SEC. 5. DVT/PE SURVEILLANCE STUDY AND REPORT.
(a) Study.--The Secretary of Health and Human Services (in this
section referred to as the ``Secretary'') shall conduct or support a
study on model systems of DVT/PE surveillance, including the use of
electronic medical record-based methods of detecting DVT and PE
International Classification of Diseases codes (commonly known as ``ICD
codes'') or other population-based surveillance.
(b) Report.--Not later than 1 year after the date of enactment of
this Act, the Secretary shall submit to Congress and the Advisory
Committee for DVT/PE Prevention established under section 4(a) a report
detailing the results of the study under subsection (a).
SEC. 6. AUTHORIZATION OF APPROPRIATIONS.
There is authorized to be appropriated to carry out this section
$20,000,000 for each of fiscal years 2025 through 2029.
<all>
Introduced in House
Introduced in House
Referred to the House Committee on Energy and Commerce.
Referred to the Subcommittee on Health.
Llama 3.2 · runs locally in your browser
Ask anything about this bill. The AI reads the full text to answer.
Enter to send · Shift+Enter for new line